Recombinant MS4A1 (Rituximab Biosimilar) antibody

Catalog No. ABIN7200660

Product Details anti-MS4A1 (Rituximab Biosimilar) Antibody

Target: MS4A1 (Rituximab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This MS4A1 (Rituximab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Purpose: Rituximab Biosimilar, CD20 Monoclonal Antibody

Specificity: The monoclonal antibody rituximab biosimilar specifically binds to the human TNF alpha.

Characteristics: Recombinant Humanized IgG1 Monoclonal Antibody.

Purification: Protein A affinity column

Purity: > 95% by SDS-PAGE under reducing conditions and HPLC.

Sterility: 0.2 μm filtered

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method.

Immunogen: The monoclonal antibody rituximab biosimilar was produced in the Rituximab biosimilar CHO stable cell line.

Clone: 10F381

Isotype: IgG1 kappa

Application Details

Application Notes: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by rituximab.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Preservative: Without preservative

Handling Advice: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Storage: -20 °C

Storage Comment: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Expiry Date: 12 months

Target Details for MS4A1 (Rituximab Biosimilar)

Target: MS4A1 (Rituximab Biosimilar)

Abstract: MS4A1 (Rituximab Biosimilar) Products

Synonyms: B1 antibody, Bp35 antibody, CD20 antibody, CVID5 antibody, LEU-16 antibody, MS4A2 antibody, S7 antibody, membrane spanning 4-domains A1 antibody, MS4A1 antibody

Target Type: Biosimilar

Background: B-lymphocyte antigen CD20 encoded by the MS4A1 gene is an activated-glycosylated phosphoprotein on the surface of all B-cells. The function of the membrane protein is to stimulate B-cell immune response, specifically against T-independent antigens though its natural ligand remains unknown. CD20 is important for the development and differentiation of B-cells into plasma cells. CD20 belongs to the membrane-spanning 4A family with common structural features, similar intron/exon splice boundaries, and unique expression patterns among hematopoietic cells and nonlymphoid tissues.

Rituximab, a chimeric anti-CD20 monoclonal antibody, destroys B cells and is used to treat diseases with excessive numbers of B cells, overactive B cells, or dysfunctional B cells, such as many lymphomas, leukemias, transplant rejection, and autoimmune disorders.